HOOKIPA Pharma Files 8-K with Corporate Details
Ticker: HOOK · Form: 8-K · Filed: Jan 7, 2025 · CIK: 1760542
| Field | Detail |
|---|---|
| Company | Hookipa Pharma Inc. (HOOK) |
| Form Type | 8-K |
| Filed Date | Jan 7, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-filing, 8-k
TL;DR
HOOKIPA Pharma filed an 8-K on Jan 7, 2025, updating corporate info. Nothing major disclosed yet.
AI Summary
HOOKIPA Pharma Inc. filed an 8-K on January 7, 2025, reporting other events and financial statements. The filing details the company's principal executive offices located at 350 Fifth Avenue, New York, NY, and its principal executive office phone number as +43 1 890 63 60. No specific material events or financial figures beyond basic company identification were detailed in the provided excerpt.
Why It Matters
This filing provides updated corporate information for HOOKIPA Pharma Inc., which is essential for investors and stakeholders to track the company's official contact and location details.
Risk Assessment
Risk Level: low — The filing is a routine 8-K reporting corporate information and does not appear to disclose any new material risks or significant business changes.
Key Players & Entities
- HOOKIPA Pharma Inc. (company) — Registrant
- January 7, 2025 (date) — Date of earliest event reported
- 350 Fifth Avenue, 72nd Floor, Suite 7240 (address) — Principal Executive Offices
- New York (location) — City of Principal Executive Offices
- NY (location) — State of Principal Executive Offices
- 10118 (zip_code) — Zip Code of Principal Executive Offices
- +43 1 890 63 60 (phone_number) — Registrant's telephone number
FAQ
What is the exact date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is January 7, 2025.
What is the full legal name of the registrant?
The exact name of the registrant is HOOKIPA Pharma Inc.
Where are HOOKIPA Pharma Inc.'s principal executive offices located?
HOOKIPA Pharma Inc.'s principal executive offices are located at 350 Fifth Avenue, 72nd Floor, Suite 7240, New York, New York, 10118.
What is the telephone number for HOOKIPA Pharma Inc.'s principal executive offices?
The registrant's telephone number, including area code, is +43 1 890 63 60.
What is the state of incorporation for HOOKIPA Pharma Inc.?
HOOKIPA Pharma Inc. is incorporated in Delaware.
Filing Stats: 512 words · 2 min read · ~2 pages · Grade level 9.9 · Accepted 2025-01-07 06:35:35
Key Financial Figures
- $0.0001 — e on which registered Common Stock, $0.0001 par value per share HOOK The Nasdaq
Filing Documents
- tm252116d1_8k.htm (8-K) — 27KB
- tm252116d1_ex99-1.htm (EX-99.1) — 34KB
- 0001104659-25-001553.txt ( ) — 242KB
- hook-20250107.xsd (EX-101.SCH) — 3KB
- hook-20250107_lab.xml (EX-101.LAB) — 33KB
- hook-20250107_pre.xml (EX-101.PRE) — 22KB
- tm252116d1_8k_htm.xml (XML) — 4KB
01 Other Information
Item 8.01 Other Information. As previously reported, on January 2, 2025, HOOKIPA Pharma Inc. (the "Company") and Poolbeg Pharma plc ("Poolbeg") released an announcement pursuant to Rule 2.4 of the U.K. City Code on Takeovers and Mergers that the Company and Poolbeg have entered into non-binding discussions for the potential acquisition by the Company of the entire issued share capital of Poolbeg (the "2.4 Announcement"). On January 7, 2025, the Company and Poolbeg released an update to the 2.4 Announcement, a copy of which is attached hereto as Exhibit 99.1 and is incorporated by reference into this Item 8.01.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits . Exhibit Number Description 99.1 Update to Announcement pursuant to Rule 2.4 of the U.K. City Code on Takeovers and Mergers, dated January 7, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 7, 2025 HOOKIPA Pharma Inc. By: /s/ Terry Coelho Name: Terry Coelho Title: Executive Vice President and Chief Financial Officer